Gyre Therapeutics (GYRE) director granted 100,000 stock options on Form 4

Rhea-AI Filing Summary

Gyre Therapeutics director Zhang Ping reported receiving a new stock option grant for 100,000 shares of the company’s common stock. The option has an exercise price of $7.31 per share and was granted on January 7, 2026. According to the filing, 25% of the option will vest on January 7, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, conditioned on Zhang’s continued service to the company. After this grant, Zhang beneficially owns 100,000 derivative securities (stock options) directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zhang Ping

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12770 HIGH BLUFF DRIVE, SUITE 150

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.31	01/07/2026		A		100,000		(1)	01/07/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. This option represents a right to purchase a total of 100,000 shares of the Issuer's common stock, 25% of which will vest on January 7, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Ruoyu Chen, as attorney-in-fact for Ping Zhang	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Gyre Therapeutics (GYRE) report for Zhang Ping?

The filing shows that director Zhang Ping was granted a stock option for 100,000 shares of Gyre Therapeutics common stock.

What is the exercise price of Zhang Ping’s Gyre Therapeutics (GYRE) stock options?

The stock option granted to Zhang Ping has an exercise price of $7.31 per share.

How do Zhang Ping’s Gyre Therapeutics (GYRE) options vest?

The option vests 25% on January 7, 2027, with the remaining 75% vesting in equal monthly installments over the next three years, subject to continued service.

How many Gyre Therapeutics (GYRE) derivative securities does Zhang Ping own after this Form 4?

After the reported transaction, Zhang Ping beneficially owns 100,000 derivative securities (stock options) directly.

What role does Zhang Ping hold at Gyre Therapeutics (GYRE)?

Zhang Ping is reported as a director of Gyre Therapeutics and is not listed as an officer or 10% owner in this filing.

Was this Gyre Therapeutics (GYRE) Form 4 filed for multiple insiders?

No. The Form 4 indicates it was filed by one reporting person, Zhang Ping.